News Releases Piper Sandler 36th Annual Healthcare Conference Thursday, December 05, 2024 at 1:30 PM EST Listen to Webcast Keyword Search Year None20242023202220212020 Date Title 12/02/24 Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference 11/12/24 Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights 11/05/24 Optinose Announces Reporting Date for Third Quarter 2024 Financial Results 10/16/24 Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 10/07/24 Optinose Appoints Terry Kohler as Chief Financial Officer 09/05/24 New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery 08/26/24 Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference 08/08/24 Optinose Reports Second Quarter 2024 Financial Results and Recent Operational Highlights 08/02/24 Optinose Announces Reporting Date for Second Quarter 2024 Financial Results 06/27/24 Expanded Access to XHANCE with Addition to National Commercial Formularies 05/17/24 Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ 05/14/24 Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights 05/10/24 Optinose Announces Reporting Date for First Quarter 2024 Financial Results 05/09/24 Optinose Announces $55 Million Registered Direct Offering 04/25/24 Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million 04/04/24 Optinose to Present at the Needham Virtual Healthcare Conference 03/15/24 XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps 03/07/24 Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights 02/29/24 Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results 01/18/24 Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
Piper Sandler 36th Annual Healthcare Conference Thursday, December 05, 2024 at 1:30 PM EST Listen to Webcast